<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00690222</url>
  </required_header>
  <id_info>
    <org_study_id>CHDA-RS/2008-024</org_study_id>
    <nct_id>NCT00690222</nct_id>
  </id_info>
  <brief_title>Intracameral Mydriasis Versus Topical Mydriasis in Cataract Surgery</brief_title>
  <official_title>A Comparison of Intracameral Phenylephrine 2% and Tropicamide 0.2% With Topical Phenylephrine 2.5% and Tropicamide 1% for Pupillary Dilation During Cataract Surgery on Patients With and Without Pseudoexfoliation Syndrome.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nova Scotia Health Authority</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nova Scotia Health Authority</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to determine if an intracameral solution of 0.2% tropicamide and 2%&#xD;
      phenylephrine can dilate the pupil for cataract surgery as well as pre-operative topical 1%&#xD;
      tropicamide and 5% phenylephrine. We will be looking at two separate groups of patients,&#xD;
      those with and those without pseudoexfoliation syndrome.&#xD;
&#xD;
      We will be looking at how each method affects the size of the pupil at the beginning and at&#xD;
      the end of cataract surgery. In addittion, we will look at what effect the two different&#xD;
      methods have on blood pressure and heart rate in the pre-operative, peri-operative and&#xD;
      post-operative periods.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Funding&#xD;
  </why_stopped>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pupil size</measure>
    <time_frame>At beginning and completion of cataract surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Peri-operatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>Peri-operatively</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Cataract</condition>
  <condition>Phacoemulsification</condition>
  <condition>Mydriasis</condition>
  <condition>Pseudoexfoliation Syndrome</condition>
  <arm_group>
    <arm_group_label>TM</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Topical mydriasis without pseudoexfoliation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ICM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intracameral mydriasis without pseudoexfoliation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TM - PXF</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Topical mydriasis with pseudoexfoliation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ICM - PXF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intracameral Mydriasis with pseudoexfoliation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intracameral injection of mydriatic agent</intervention_name>
    <description>A mixture of 0.2 % tropicamide and 2% phenylephrine will be injected into the anterior chamber at the beginning of surgery</description>
    <arm_group_label>ICM</arm_group_label>
    <arm_group_label>ICM - PXF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to give consent&#xD;
&#xD;
          -  Greater than 18 years of age&#xD;
&#xD;
          -  Planned clear cornea cataract extraction and placement of foldable posterior chamber&#xD;
             intraocular lens&#xD;
&#xD;
          -  No secondary procedure planned (i.e. trabeculectomy, keratectomy, corneal transplant,&#xD;
             vitreo-retinal procedure etc.)&#xD;
&#xD;
          -  Systemic condition capable of undergoing topical anesthesia&#xD;
&#xD;
          -  No previous intraocular surgery&#xD;
&#xD;
          -  Pseudoexfoliation syndrome (PXF) for group 1&#xD;
&#xD;
          -  No Pseudoexfoliation syndrome for group 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not fulfilling inclusion criteria&#xD;
&#xD;
          -  Any iris pathology including but not limited to posterior synechia, iridocorneal&#xD;
             endothelial syndrome, corectopia, traumatic mydriasis, Horner's syndrome, Adie's&#xD;
             pupil, cyclodialysis, iridodialysis&#xD;
&#xD;
          -  Previous or concurrent use of FlomaxÂ® or similar alpha-antagonist medication&#xD;
&#xD;
          -  Corneal pathology affecting pupil magnification or measurement (keratoconus,&#xD;
             peripheral thinning, sclerocornea, scarring)&#xD;
&#xD;
          -  Uncontrolled Hypertension (greater than 170/90 on pre-operative assessment on day of&#xD;
             surgery as measured by automated DATEX monitor)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Capital District Health Authority</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <study_first_submitted>May 30, 2008</study_first_submitted>
  <study_first_submitted_qc>May 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2008</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cataract surgery</keyword>
  <keyword>phacoemulsification</keyword>
  <keyword>pupil</keyword>
  <keyword>dilation</keyword>
  <keyword>mydriasis</keyword>
  <keyword>intracameral</keyword>
  <keyword>topical</keyword>
  <keyword>pseudoexfoliation syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Mydriasis</mesh_term>
    <mesh_term>Exfoliation Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mydriatics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

